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Context: The genetic pathways involved in medullary thyroid carcinomas (MTC), except for RET
mutations, are largely unknown, as is the detailedmappingof proteins activated as a consequence
of RET tyrosine kinase phosphorylation.
Objective: The present study was designed to screen for the presence of mutations in other genes
downstream to RET activation and to detect the activation patterns of a panel of intracellular
regulators of cell growth.
Design: Forty-nine cases of MTCwere analyzed for mutations in RET, BRAF, N-, H-, and K-RAS, and
phosphatidylinositol-3 (PI3) kinase genes. Immunohistochemical analysis was performed using
antibodies against several intracellular transducers. The effect of mammalian target of rapamycin
(mTOR) inhibitionwas assessed in vitro onto TT cells bymeans of methyl thiazolyl tetrazolium and
Western blot assays.
Results: BRAF, K-, H-, and N-RAS, and PI3 kinase mutations were absent in all cases examined.
Germline RET mutations were detected in 20% of cases overall, whereas somatic RET mutations
represented 53% of sporadic tumors. RET mutational status was associated to age, presence of
multifocal tumors, and nodal status, but not disease outcome. Protein expression of markers
investigatedwas highly heterogeneous, with a strong association between phospho-mTOR, phos-
pho-AKT, and phospho-p70S6K, positively correlated to the presence of germline RET mutations.
Moreover, selective mTOR inhibition affected cell proliferation of RET-mutant TT cells.
Conclusions: Taken together, our findings indicate that mTOR intracellular signaling pathway is
functionally activated inMTCwith a preferential expression in caseswith germline RETmutations;
genes downstream to RET tyrosine kinase such as BRAF, RAS isoforms, and PI3 kinase are not
mutated in MTC. (J Clin Endocrinol Metab 96: 2146–2153, 2011)
Medullary thyroid cancer is a neuroendocrine tumorderived from thyroid C cells, and it accounts for
approximately 5% of all thyroid malignancies (1). Germ-
line RET mutations are responsible for inherited tumors
(25%of the cases),whereas somaticRETmutations occur
in one third of sporadic cases. However, the genetic path-
ways involved inRETwild-typemedullary carcinomasare
largely unknown.
Few data from genomic profiling studies—bymeans of
high-resolution array comparative genomic hybridiza-
tion—detected clusters of allelic imbalances (mostly
losses) frequently occurring in medullary carcinomas, al-
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though such genetic abnormalities were similar in cases
without RET mutations as well as in those harboring so-
matic or germline pointmutations (2). These data support
the existence of several putative suppressor genes involved
in medullary carcinoma tumorigenesis, although the lack
of association with RET mutations seems to suggest that
most, if not all, such abnormalities are acquired during
cancer progression rather than associated to early initia-
tion. Gene expression profiling on cellular models har-
boring different RET mutations (MEN2A and MEN2B)
showed that these mutants modulated genes with similar
functional ontologies (3). Moreover, microarray analysis
ofmedullary carcinoma tumor samples identified two sep-
arate clusters of tumors, with specific genes—such as
pleiotrophin, further validated by real-time PCR analysis
and immunohistochemistry—associated with aggressive
features, but not with specific RET mutation status (4).
Taken together, all these data support the existence of
peculiar molecular profiles in medullary thyroid cancer
that are not directly related to the presence and type of
activating mutations of the RET gene.
Thus, the molecular background of tumors with wild-
type RET status remains unclear. Mutations in genes fre-
quently involved in thyroid tumorigenesis, such as RAS
isoforms, BRAF, and phosphatidylinositol-3 (PI3) kinase
have been investigated in medullary thyroid carcinoma
only in a limited series of cases. The latter gene has been
tested in 13 cases (all negative) in a single study (5),
whereas BRAF gene has been found to lack mutations in
two small series (6, 7) but was apparently mutated in up
to 68% of cases in another series of 44 cases from Greece
(8). In this same study, K-RAS mutations were also de-
tected in about 40% of medullary thyroid cancers, a find-
ing that has never been confirmed or called into question
in the literature.
Concerning protein expression profiling, severalmark-
ers related to growth control and invasion/metastatic po-
tential have been tested in medullary carcinoma, but a
single study compared the expression of one of these with
RET mutation status (9); in this study, nuclear factor-B,
amolecule involved in several biological responses includ-
ing proliferation, migration, and apoptosis and activated
by multiple intracellular pathways, was found to be al-
tered more frequently in RET-mutated compared with
RET-wild-type cases. By contrast, proteins that are acti-
vated as a consequence of RET tyrosine kinase phosphor-
ylation have never been extensively investigated in tumor
samples ofmedullary thyroid carcinoma. Thesemolecules
include phospho-MAPK (10) and Stat-3 (11) that are di-
rectly activated by RET tyrosine kinase, and galectin-3,
which has been shown to be expressed in medullary thy-
roid cancer (12) andmodulated by nuclear factor-B (13).
Moreover, several examples of evidence support the ac-
tivation of the AKT/mammalian target of rapamycin
(mTOR) signaling cascade in medullary thyroid cancer
(14, 15), and this pathway seems to be a candidate for
target therapies in medullary thyroid carcinoma due to in
vitro evidence that indirect blocking, such as the use of PI3
kinase inhibitors (16), or direct inhibition of mTOR (17)
mediates induction of apoptosis and decrease in cell via-
bility of medullary carcinoma TT cell line.
Basedon suchaheterogeneousbackground, thepresent
study was designed in a large series of medullary thyroid
carcinomaswith a 3-fold aim: 1) to screen for the presence
of mutations in several genes involved in thyroid carcino-
genesis; 2) to detect the prevalence of expression of a panel
of intracellular regulators of cell growth; and 3) to com-
pare their activation patterns with RET mutation status.
Subjects and Methods
Case selection
Sixty-five cases ofmedullary thyroid carcinomawere selected
from the databases of theDivision of Pathology of theUniversity
of Turin (from years 1983 to 2007). Eleven cases occurred as
familial tumors in the setting of MEN2 syndrome (one case as
familial medullary thyroid cancer, eight cases as MEN2A, and
two cases asMEN2B forms), as proved by genetic testing of RET
exons 8, 10, 11, and 13–16 in peripheral blood samples per-
formed elsewhere, determining the presence of germline RET
mutations. The remaining cases were apparently sporadic. In-
clusion criteria were the availability of representative hematox-
ylin-eosin sections for histological reviewandparaffin blocks for
immunohistochemistry and molecular testing, and of clinical
pathological information.
The study has been approved by the Institutional Review
Board of San Luigi Hospital. All pathological material was de-
TABLE 1. PCR and sequencing primer sequences used for RET and PI3K mutations analysis
Gene (exon) Codons Forward PCR primer Reverse PCR primer
RET (11) NG_007489 630–634 5-AGCCATGAGGCAGAGCATACG-3 B-5-GACAGCGGCTGCGATCAC-3
RET (15) NG_007489 883 B-5GGGACTTGGCAGCCAGAAA-3 5-GGGACAAGCCGAAATCCG-3
RET (16) NG_007489 918 B-5GGGCCTGGCCTTCTCCTTTA-3 5-CGTCGTGGCCCCACTACA-3
PI3K (9) NG_012113 542–546 5-GCACTTACCTGTGACTCCATAGAA3 B-5-CAGCTCAAAGCAATTTCTACACG3
PI3K (20) NG_012113 1007–1031 5-TAGCTATTCGACAGCATGCCAAT-3 B-5-TGAAATACTCCAAAGCCTCTTGC-3
PI3K (20) NG_012113 1041–1060 5-AGCAAGAGGCTTTGGAG-TATTTC-3 B-5-GCCTGCTGAGAGTTATTAACAGTG-3
GenBank accession numbers are shown in brackets. B, Biotin; Ann T, annealing temperature; bp, base pairs.
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identified using codes that were not available to the researchers
involved in the study.
Molecular analysis
Nucleic acid isolation
Genomic DNA was isolated from formalin-fixed, paraffin-
embedded, neoplastic and corresponding normal thyroid tissues
using the standard proteinase K-phenol-chloroform extraction
method. RNA was isolated from paraffin-embedded material
using the high pure RNA paraffin kit (Roche, Mannheim, Ger-
many) following manufacturer’s instructions. The quantity of
isolated DNA and RNA was assessed using a Biophotometer
(Eppendorf, Hamburg, Germany).
Point mutation analysis
The presence of BRAF V600E and K601E,NRAS codon 61,
HRAS codon 61, and KRAS codons 12 and 13 point mutations
was analyzed using pyrosequencing method and PCR primers
following previously published protocols (18). RET exons 11,
15, and 16 and PI3 kinase exons 9 and 20 were analyzed in both
tumor and normal peritumoral thyroid tissue by means of py-
rosequencing method. PCR and sequencing primers were de-
signed using the PSQ Assay Design Software version 1.0.6
(Biotage AB, Uppsala, Sweden). One primer of each pair has a
5-biotin label necessary for post-PCR processing. The corre-
sponding primer sequences, amplicon sizes, and annealing tem-
peratures are shown in Table 1. PCR amplification for the
pyrosequencing assay was performed according to standard
protocols. The amplicons were mixed with sequencing primers,
and sequencing was performed using a PyroGold reagent Kit
(Biotage AB) according to the manufacturer’s protocol. Results
were analyzed using the PSQ-96 MA 2.0.2 software.
Immunohistochemistry
Eleven tissue microarrays were prepared for immunohisto-
chemical analysis using the Quick-RAY tissue arrayer (Bio-Op-
tica,Milan, Italy). For each case, two different samples of tumor
tissue were selected from the more representative hematoxylin-
eosin-stained slide, and tissue cylinders with a diameter of 3 mm
werepunchedunder the stereomicroscope fromthe specific areas
of the “donor” block and brought into the “recipient” paraffin
block.
The cases were analyzed by means of immunohistochemistry
using the following antibodies: phospho-mTOR (rabbit mono-
clonal, 49F9, Ser2448, diluted 1:100; Cell Signaling Tech, Bev-
erly,MA), phospho-p70S6K (mousemonoclonal, 1A5, Thr389,
diluted 1:400; Cell Signaling), phospho-AMPK (rabbit mono-
clonal, 40H9, Thr172, diluted 1:100; Cell Signaling), phospho-
AKT (rabbit monoclonal, 736E11, Ser473, diluted 1:1000; Cell
Signaling), Stat-3 (mouse monoclonal, F-2, diluted 1:100; Santa
Cruz Biotechnology, Santa Cruz, CA), phospho-MAPK (p44–
42) (polyclonal, Thr202/Tyr204, diluted 1:250; Cell Signaling),
and galectin-3 (ratmonoclonal, diluted 1:500;Mabtech,Nacka,
Sweden).
Immunohistochemical reactions were performed according
to standard automated immunohistochemical procedure (Dako
Autostainer, Glostrup, Denmark), and immunoreactions were
revealed by means of a biotin-free, dextran-chain detection sys-
tem (Envision; DakoCytomation, Glostrup, Denmark) and de-
veloped using diaminobenzidine as the chromogen. For all an-
tibodies, immunohistochemical staining was scored as a sum of
the two scores as follows: score 0, no immunoreactivity; score 1,
no more than 25% of positive tumor cells; score 2, 25–50% of
positive tumor cells; and score 3, more than 50% of positive
tumor cells. For statistical purposes, scores were considered in-
dividually for Spearman correlation test and were grouped as
“negative” (score 0 and 1) and “positive” (scores 2 and 3) for
clinical pathological and molecular correlations.
Cell culture, proliferation assay, and Western blot
The RET germline mutantMTC cell line (TT) was purchased
from ATCC (LGC Standards s.r.l., Sesto San Giovanni, Milan,
Italy); a pancreatic neuroendocrine tumor cell line (BON-1) was
kindly provided byDr. BertramWiedenmann (University of Ber-
lin) and served as a control. Cell lines were maintained in Ham’s
F12 (TT) and in 1:1 DMEM/F12 mixture (BON-1) supple-
mentedwith 10% fetal calf serum, 2 nMglutamine, penicillin (25
U/ml), and streptomycin (25 g/ml) (all from Sigma-Aldrich, St.
Louis, MO) in a humidified atmosphere containing 5% CO2 at
37 C. BON-1 and TT cell lines were plated into 96-well plates in
triplicate and treated with different doses of RAD001 (from 0.1
nmol/liter to 1 mol/liter; Novartis Pharma AG, Basel, Switzer-
land) for 48 and 72 h. Cell viability was evaluated by adding 0.5
mg/ml methyl thiazolyl tetrazolium (MTT; Sigma-Aldrich) so-
lution, incubating for 4 h, then adding 100 m dimethyl sulfox-
ide. The 570-nm absorbance was measured using a microplate
reader (model540;Bio-Rad,Hercules,CA), anddifferenceswere
evaluated by means of Student’s t test.
Western blot experiments were performed on protein ex-
tracts at basal or after 24 h of treatment with different doses of
RAD001 (from 0.1 to 10 nmol/liter). All samples were homog-
enized and lysated in Tris-NaCP-EDTA lysis buffer supple-
mented with 1% protease inhibitor cocktail (Complete; Roche
Diagnostic Corporation, Indianapolis, IN). The protein concen-
tration was evaluated using BCA protein assay kit (Pierce, Mil-
waukee, WI), and 50 g of protein were resolved in 8% SDS-
PAGE and transferred to nitrocellulose membranes for each
experiment. The membrane blots were blocked for 1 h with 5%
BSA in Tris-buffered saline-Tween 0.1% and incubated over-
TABLE 1. Continued
Sequencing primer Ann T (C) Product size (bp)
5-CCCACCCACAGATCC-3 55 132
5-TTCATCTTCCGCCCC-3 55 72
5-ATATGATCAAAAAGGGATTCA-3 57 221
5-CCTGTGACTCCATAGAAAA-3 57 111
5-TCTTCATAAATCTTTTCTCA-3 55 153
5-CAAGAGGCTTTGGAGTA-3 57 181
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night at 4 C with the same phospho-mTOR and phospho-
p70S6K antibodies used for immunohistochemistry and -actin
(SantaCruz Biotechnology), all diluted 1:1000. Immunoreactive
proteins were visualized using horseradish peroxidase-conju-
gated antimouse or antirabbit antibody (1:3000 and 1:1000,
respectively) and enhanced chemiluminescence (Amersham Bio-
sciences, Piscataway, NJ) as the substrate. The OD of the ap-
propriately sized bandswasmeasured using the ImageJ free soft-
ware (http://rsbweb.nih.gov/ij/).
Statistical analysis
The correlation between genetic alterations, known clinical
pathological parameters, and immunohistochemical findings was
assessedby2 test or nonparametric t test.Univariate survival anal-
ysis was based on theKaplan-Meier product limit estimate of over-
all survival distribution. Unadjusted differences between survival
curves were tested using the log rank test. The Spearman test was
used to analyze the correlation index among markers expression.
The level of significancewas set atP0.05. Statistical analysiswas
performed using the GraphPad Prism 4 (GraphPad Software, Inc.,
San Diego, CA) and SPSS (SPSS Inc., Chicago, IL) software.
Results
Molecular profile
Sixteen cases were excluded from further molecular
analysis due to very low amount or poor quality of DNA
extracted.
BRAF; K-, H-, and N-RAS; and PI3 kinase mutations
were absent in all cases examined. RET germline muta-
tions in MEN2 patients, detected elsewhere, included
Val804Met (one case), Cys618Arg (two cases), Cys634Tyr
(five cases), Cys634Arg (one case), and Met918Thr (two
cases) substitutions. The remaining 38 clinically sporadic
cases showed no mutations in exons 11, 15, and 16 in
nontumoral DNA, whereas tumor DNA harbored the
Met918Thr mutation in 16 cases, the Cys630Ala muta-
tion in twocases, theCys634Argmutation inone case, and
thedelta6mutation in exon11 (nucleotides 1894–1899of
the corresponding RET cDNA) (19) in one case.
RET mutational status was associated to age, presence
ofmultifocal tumors, andnodal status (Table 2):mean age
was lower in RET-positive cases (P  0.03) and, among
them, in patients with germline mutations (P  0.023);
multifocalitywas present in aminority of sporadic tumors
but associated to the presence of germline RETmutations
TABLE 2. Clinical pathological features of 49 cases of medullary carcinoma according to RET mutational status
RET mutational status F/M ratio
Mean age 
SEM (yr)
Multifocal
(rate)
Mean size 
SEM (mm)
pT >3
stage (rate)
pN
stage
(rate)
AWD/DOD
status (rate)
Absence of RET mutations (18) 1.2 60.3  2.2 2/17 30.92  5.3 5/17 4/12 4/13
Sporadic RET mutations (20) 3 55.3  3.1 3/20 26.7  3.4 8/20 11/13 7/13
Germline RET mutations (11) 2.6 40.4  6.2 6/10 21.6  3.5 4/10 7/9 5/10
P all groups P  0.32 P  0.003 P  0.008 P  0.45 P  0.77 P  0.017 P  0.45
P RET vs. RET P  0.24 P  0.03 P  0.29 P  0.32 P  0.68 P  0.014 P  0.37
P sporadic vs.
germline RET
P  0.77 P  0.02 P  0.03 P  0.35 P  0.69 P  0.88 P  0.81
IM RET mutations (13) 3.3 45.1  4.7 33.3% 22.7  3.2 3/12 6/9 3/12
TK RET mutations (18) 2.6 53.6  4.2 27.7% 26.6  3.7 9/18 12/13 9/15
P  0.90 P  0.19 P  0.93 P  0.46 P  0.32 P  0.33 P  0.21
IM, Mutations in the iuxta-membrane domain; TK, mutations in the tyrosine kinase domain; F, female; M, male; AWD, alive with disease status;
DOD, died of disease status; pT, pathological tumor stage; pN, pathological node stage. Bold indicates statistical significance. Numbers in
parentheses indicate number of cases.
FIG. 1. A, Graph distribution of individual immunohistochemical markers
in medullary carcinomas, divided according to immunohistochemical
score. B–H, Representative illustrations of phospho-mTOR, phospho-
p70S6K, phospho-AMPK, phospho-AKT, phospho-MAPK, Stat-3, and
galectin-3, respectively (immunoperoxidase; original magnification,400
for all panels).
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(P  0.008); moreover, the presence of lymph node me-
tastases was associated to RET point mutations (P 
0.014), irrespective of somatic or germline. By contrast,
the presence or type of RETmutations was not correlated
to sex, tumor size, stage, disease status, and survival.
Immunohistochemistry
Immunohistochemical evaluations were performed in
the 49 cases suitable for molecular analysis. The distribu-
tion of individual scores for eachmarker is reported in Fig.
1. Positivity (scores 2 and 3) ranged from 24% for phos-
pho-MAPK to 76% for phospho-AMPK. Correlation
analysis (Table 3) demonstrated a strong association be-
tween phospho-mTOR, phospho-p70S6K, and phospho-
AKT, suggesting an activated status of the AKT/mTOR
pathway in these cases; phospho-p70S6Kwas also slightly
associated with phospho-MAPK (R  0.33) and galec-
tin-3 (R 0.34), but phospho-AKT and phospho-mTOR
were not.With respect to clinical pathological correlation,
noneof themarkers investigatedwasdirectly associated to
clinical (sex, age, disease status) or pathological (size,mul-
tifocality, pathological stage) features. The presence of
positive phospho-mTOR immunoreactivity was more
prevalent in node-negative (69% of cases) compared with
node-positive cases (36%of cases), although not reaching
statistical significance (P0.102). Bymeans of univariate
analysis, all markers investigated failed to demonstrate a
prognostic impact.
When checking the expression of these markers in cor-
relation with RET mutation status (Table 4), phospho-
mTOR and phospho-p70S6K showed the same profile,
being expressed predominantly in cases harboring germ-
lineRETmutations, irrespective ofwhether themutations
were in codons coding amino acids in the iuxta-membrane
or tyrosine kinase portion of the receptor. Phospho-
MAPK was positive in cases with RET mutations only,
both sporadic or germline, except for one sporadic case
lacking somatic RET mutation.
In vitro mTOR pathway inhibition
TT and BON-1 cell lines showed a differential sensi-
tivity to mTOR inhibition (Fig. 2) with a significant re-
duction of cell viability at high doses. Western blot anal-
ysis showed that in both cell lines RAD001 strongly
inhibited phosphorylation status of phospho-mTOR and
phospho-p70S6K.
TABLE 3. Correlation among the immunohistochemical expression of investigated molecules according to the
Spearman method
p-p70S6K p-AMPK p-AKT p-MAPK STAT-3 GAL-3
p-mTOR R  0.4636 R  0.037 R  0.304 R  0.1581 R  0.2721 R  0.2176
P 0.0012 0.8047 0.024 0.2884 0.0643 0.1417
p-p70S6K R  0.2183 R  0.2716 R  0.3382 R  0.2404 R  0.3420
P 0.1450 0.0419 0.0215 0.1036 0.0215
p-AMPK R  0.0539 R  0.2541 R  0.1513 R  0.0872
P 0.7216 0.0884 0.3156 0.5688
p-AKT R  0.1665 R  0.1301 R  0.1368
P 0.2742 0.3942 0.3757
p-MAPK 0.1313 0.1525
P 0.3789 0.3115
STAT-3 0.2223
P 0.1377
Bold indicates statistical significance.
TABLE 4. Immunoprofiling of 49 cases of medullary carcinoma according to RET mutational status
RET mutational status
Rate immunohistochemistry ve cases
p-mTOR p-p70S6K p-AMPK p-AKT p-MAPK Stat-3 Gal-3
Absence of RET mutations (18) 11/18 7/18 11/18 10/18 1/18 11/18 13/18
Sporadic RET mutations (20) 5/20 9/20 16/20 16/20 6/20 12/20 15/20
Germline RET mutations (11) 9/11 10/11 10/11 7/11 5/11 9/11 8/11
P all groups P  0.006 P  0.016 P  0.16 P  0.27 P  0.04 P  0.42 P  0.98
P RET vs. RET P  0.43 P  0.22 P  0.15 P  0.23 P  0.045 P  0.87 P  0.85
P sporadic vs. germline RET P  0.008 P  0.034 P  0.78 P  0.88 P  0.64 P  0.40 P  0.77
IM RET mutations (13) 6/13 9/13 11/13 7/13 5/13 10/13 9/13
TK RET mutations (18) 8/18 10/18 15/18 16/18 6/18 11/18 14/18
P  0.78 P  0.69 P  0.69 P  0.07 P  0.93 P  0.59 P  0.90
IM, Mutations in the iuxta-membrane domain; TK, mutations in the tyrosine kinase domain; IHC, immunohistochemistry; Gal-3, galectin-3.
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Discussion
Seventeen years passed since the discovery that RET pro-
tooncogene mutations are responsible for inherited (20)
and sporadic (21) medullary thyroid carcinoma. How-
ever, RET mutations remain the only well-recognized ge-
netic alteration occurring in this tumor type, bearing also
prognostic significance (22), whereas the molecular
pathogenesis of up to two thirds of sporadic cases remains
unclear. Point mutations of genes involved in thyroid tu-
morigenesis and linked to RET pathway have been
screened in limited case series. Therefore, a first aim of the
present studywas to determine inRETwild type aswell as
in RET mutated medullary carcinomas the occurrence of
point mutations in genes involved in thyroid tumorigen-
esis and acting downstream to RET tyrosine kinase acti-
vation. Our study results confirm the data already pub-
lished in a small series of cases (5) showing that the PI3
kinase gene is not mutated in medullary thyroid cancer,
and are in line with the majority of the authors that failed
to demonstrate the presence of BRAF mutations in this
tumor type,whereas they contrastwith the very high prev-
alence encountered in aGreek study (8); although ethnical
differences are to be considered, the significance of such a
discrepancy is unclear. Moreover, we could not confirm
the high prevalence of K-RAS mutations described in this
same study (8), and we could not detect any mutation in
N- andH-RAS isoforms, frequently altered in several thy-
roid tumor histotypes. So far, we could not detect any
molecular alteration in the genes investigated, either as-
sociated to RETmutations or in RETwild-type tumors in
our series of medullary carcinomas.
The further step of this study was therefore to analyze
the protein expression of a panel of signal transducers that
act downstream to RET tyrosine kinase activation (23)
and have never been investigated in medullary carcinoma
compared with the RETmolecular profile. This approach
had the dual scope of defining protein profiles of both
pathogenetic and therapeutic interest because several in-
tracellular transducers, including those analyzed in this
study, are relevant for tumor initiation and progression
but are also potential candidates for targeted therapies
(24). Although the analysis of phosphorylated proteins in
formalin-fixed, paraffin-embedded tissue samples using
specific antibodies is potentially affected by artifacts re-
lated to tissue preservation, the immunohistochemical ap-
proach allows the evaluation of retrospective series with
long follow-up data and the cellular/subcellular localiza-
tion of target proteins, as well. Our data at the tissue level
showed that the AKT/mTOR pathway is highly activated
in medullary carcinoma due the strong reciprocal associ-
ation between the molecules involved in this intracellular
cascade. Moreover, phospho-mTOR and its downstream
FIG. 2. Methyl thiazolyl tetrazolium assay (A) and Western blot analysis (B), including densitometric graph and corresponding blot of BON-1 and
TT cells under RAD001 treatment. *, P 	 0.05; and **, P 	 0,001, compared with untreated cells. bas, Basal condition.
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activator phospho-p70S6K were correlated to RET mu-
tation status because the vast majority of cases with germ-
line RET mutations were positive for both markers. In-
terestingly, the association was not depending on the type
(codons of the iuxta-membrane or of the tyrosine kinase
portion of the receptors) but on the hereditary nature of
the mutation. By contrast, medullary carcinomas with
sporadic RET mutations or with RET wild type showed
heterogeneous expression of AKT/mTOR pathway mol-
ecules, thus suggesting alternative activation mechanisms
that still need to be further elucidated. A major limitation
of this study is represented by the lack of in vitro MTC
models harboring different (germline vs. somatic) or lack-
ingRETmutations thatmightbe employed to speculateon
the molecular mechanisms subtending the apparently se-
lective activation of mTOR pathway by specific RETmu-
tations, and our in vitro data on TT cells could only sup-
port the functional activation of mTOR pathway but not
prove a mechanistic link with the presence of a germline
RET mutation. It is of clinical relevance, however, irre-
spective of the pathogenetic interest of these observa-
tions, that about 50% of cases with medullary carcinoma
showed expression of phospho-mTORbecause, at least in
in vitro lung carcinoid models, endogenous levels of this
molecule have been shown to be indicative of response to
mTOR inhibitors (25). Moreover, we could confirm pre-
viously published data in vitro (17) that the selective in-
hibition of mTOR pathway in a germline-RET mutated
MTC cell line is effective to decrease cell viability and
block the phosphorylated status of mTOR signaling mol-
ecules. As for the other molecules investigated, a hetero-
geneous distribution was observed in our case series, with
the exception of phospho-MAPK that was expressed al-
most exclusively in cases harboring somatic or germline
RET mutations, a finding that suggests a potential role of
MAPK inhibition as a therapeutic strategy for RET-mu-
tatedMTCthat needs tobe validated in in vitro and in vivo
studies. However, none of the markers investigated was
inversely correlated with any of the other molecules, thus
suggesting the absence of mutually exclusive intracellular
signaling activation patterns in medullary carcinoma that
would have supported unique, although undiscovered,
molecular alterations with special reference to RET wild-
type cases. Clinical pathological correlations failed to
show any association between the markers investigated
and any parameter considered (including survival), dem-
onstrating thatnoneof thesemarkers is associated toprog-
nosis, which conversely still remains largely unpredict-
able, with stage still being the most relevant prognostic
indicator (26).
Taken together, our findings indicate that intracellular
signaling pathways are heterogeneously activated in med-
ullary thyroid carcinoma; RET mutation profile is asso-
ciated to the preferential expression of AKT/mTOR and,
to a lower extent, MAPK signaling, but in the absence of
mutations in genes downstream to RET tyrosine kinase
such as BRAF, RAS isoforms, and PI3 kinase, the mech-
anisms responsible for the functional activation of intra-
cellular signaling cascades promoting cell growth are still
unknown in medullary thyroid cancer.
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